Nine @entity1 with @entity43 and @entity5 treated with IV @entity2663 chemotherapy (30 mg/m2/30 min) entered this study. Plasma and peritoneal fluid levels were measured by an HPLC method with electrochemical detection. Plasma decay kinetics followed a triexponential function. A high variability of drug diffusion in @entity843 was noticed. Peak concentrations in @entity843 ranged from 1.6% to 20.5% of serum peak concentration. The concentration in peritoneal fluid reached a maximum level 6 h after the infusion ended. @entity2663 was less slowly eliminated from @entity843 than from serum. The exposure of the inflammatory peritoneal fluid to the drug expressed by area under the concentration-time curve (AUC) was also subject to significant interindividual variation, ranging from 223 to 2332 micrograms/ml X min. However, the peritoneal AUC was correlated with serum AUC and with the systemic clearance of the drug. A significant relationship between gamma glutamyltranspeptidase and both systemic clearance and either the serum or the peritoneal AUC was found, suggesting that liver plays a role in drug disposition.

Pharmacokinetics of @entity2663 ( @entity2663 ) after IV administration in serum and @entity5 of @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma'] @entity2663 :: ('MESH:D013713', 'Chemical') :: ['teniposide', 'Teniposide'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant ascites'] @entity843 :: ('MESH:D001201', 'Disease') :: ['ascites']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian carcinoma']
